In vitro activity of Iclaprim against Methicillin-resistant Staphylococcus aureus nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A pilot study
| Autor: | Stephen Hawser, Curtis G. Gemmell, David B. Huang, Daniel F. Sahm |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Article Subject medicine.drug_class 030106 microbiology Antibiotics Infectious and parasitic diseases RC109-216 medicine.disease_cause Microbiology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Antibiotic resistance medicine polycyclic compounds 030212 general & internal medicine business.industry biochemical phenomena metabolism and nutrition bacterial infections and mycoses Methicillin-resistant Staphylococcus aureus QR1-502 Infectious Diseases chemistry Staphylococcus aureus Linezolid Iclaprim Vancomycin Daptomycin business medicine.drug Research Article |
| Zdroj: | The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien des Maladies Infectieuses et de la Microbiologie Médicale Canadian Journal of Infectious Diseases and Medical Microbiology, Vol 2017 (2017) |
| ISSN: | 1712-9532 |
| Popis: | Iclaprim is a bacterial dihydrofolate reductase inhibitor in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections and hospital-acquired bacterial pneumonia caused by Gram-positive bacteria. Daptomycin, linezolid, and vancomycin are commonly used antibiotics for these indications. With increased selective pressure to these antibiotics, outbreaks of bacterial resistance to these antibiotics have been reported. This in vitro pilot study evaluated the activity of iclaprim against methicillin-resistant Staphylococcus aureus (MRSA) isolates, which were also not susceptible to daptomycin, linezolid, or vancomycin. Iclaprim had an MIC ≤ 1 µg/ml to the majority of MRSA isolates that were nonsusceptible to daptomycin (5 of 7 (71.4%)), linezolid (26 of 26 (100%)), or vancomycin (19 of 28 (66.7%)). In the analysis of time-kill curves, iclaprim demonstrated ≥ 3 log10 reduction in CFU/mL at 4–8 hours for tested strains and isolates nonsusceptible to daptomycin, linezolid, or vancomycin. Together, these data support the use of iclaprim in serious infections caused by MRSA nonsusceptible to daptomycin, linezolid, or vancomycin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text